Edrecolomab

Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.

Edrecolomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	EpCAM (17-1A)
Clinical data
Trade names	Panorex
ATC code	L01FX01 (WHO)
Identifiers
CAS Number	156586-89-9 N
DrugBank	DB13375 Y
ChemSpider	none
UNII	0KYI9U9FSJ
NY (what is this?)  (verify)

Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).^[1][2] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.^[3]

Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.

References

1. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. (May 1994). "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group". Lancet. 343 (8907): 1177–83. doi:10.1016/s0140-6736(94)92398-1. PMID 7909866. S2CID 45574458.
2. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, et al. (August 2002). "Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study". Lancet. 360 (9334): 671–7. doi:10.1016/S0140-6736(02)09836-7. PMID 12241873. S2CID 42391189.
3. Colacchio TA, Niedzwiecki D, Compton C, Warren R, Benson AI, Goldberg R, Kerr D, Fields A, Hollis D, Mayer R (July 2004). "Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)". Journal of Clinical Oncology. 22 (14_suppl): 3522. doi:10.1200/jco.2004.22.90140.3522.